Osteotech — Proxy Contest (August 2010)
44 slides from Osteotech's proxy contest presentation, Aug 12, 2010
Slide 1: Company Overview - Proxy Contest August 2010
www.osteotech.com Leader in Biologic Healing Combining Safety, Science & Technology NASDAQ Global Market: OSTE Company Overview Proxy Contest August 2010
Slide 2: Company Profile
3 Company Profile Company Founded: 1986 Public Offering: NASDAQ 1991 Headquarters: Eatontown, New Jersey Employees: 280 Shares Outstanding: 18.2 million Locations: New Jersey Clermont-Ferrand, France Sofia, Bulgaria Emerging leader in regenerative healing with the most comprehensive portfolio of fir
Slide 3: Executive Summary
Executive Summary Since 2006, we have executed on a plan to turnaround Osteotech's business and prospects, transitioning to our current position as a leading biologics and technology leader in regenerative medicine from a commodity based processing company. In short we have - Developed three new and
Slide 4: Proxy Contest Overview
Proxy Contest Overview If elected, the dissident stockholders' nominees plan to: Undertake an in-depth review of our business lines/product development programs Optimize cost structure and maximize operating efficiencies Redeem the rights plan/remove the "poison put" from the credit agreement Retain
Slide 5: Historical Context
Historical Context After a strategic assessment in late 2005, the Board and its new management team lead by Sam Owusu-Akyaw began a multi-year process in 2006 to "turnaround" the business because: The key franchise, Grafton(r) DBM, had become a commodity business with intense competition, numerous c
Slide 6: Our Strategic Plan
Our Strategic Plan To address these and other business issues, we have been executing on three key strategic imperatives over the past few years which we have discussed with our investors and shareholders numerous times: Re-invigorate R&D to generate new product technologies with short- term and lon
Slide 7: Re-invigorate R&D
Re-invigorate R&D Developed three new, innovative technology platforms (MagniFuse(tm), Plexur (r) and HCT(tm)) Each platform has an underlying long-term product development strategy, and Current product offerings were launched in 2009 or are currently under FDA review Procedure Focus based New Produ
Slide 8: From Tissue Processor to Biologics Innovator
From Tissue Processor to Biologics Innovator
Slide 9: Market Opportunity
Market Opportunity Osteotech's new product franchise opens up new market opportunities With the launches of MagniFuse(tm) and Plexur M(r), we are now able to effectively compete in the full biologics market estimated at $1.9 billion The market opportunity for Osteotech's legacy product lines is appr
Slide 10: Product Launch Update
Product Launch Update Overall new product revenue continues to grow increasing to $2.5M in 2Q 2010 from $1.8M in 1Q 2010 and $1.1M in 4Q 2009 National product launches were executed for Plexur M(r) in March and MagniFuse(tm) in April MagniFuse(tm) revenue has grown to $1.3M in 2Q 2010 in only nine m
Slide 11: Improved Financial Results
Improved Financial Results Leveraged the assets and business prospects throughout the turnaround to provide cash to fund all of the initiatives. Solidified our balance sheet and utilized our cash to make the right investments for the long-term prospects of the business. Prepared for and transitioned
Slide 12: Improve Gross Margins/Profitability and Generate Cash
Improve Gross Margins/Profitability and Generate Cash Gross margins improved to ~ 50% from 34% in 2005 Profitable in 2006, 2007 and 2008 after losing $21.1M in 2005 Unprofitable in 2009 during transition away from MTF relationship, weathering world-wide economic meltdown and self-imposed inventory q
Slide 13: 2009 - The Transition Year
2009 - The Transition Year 2009 represented the key transition year Realized the vision as a biologics innovator instead of a tissue processer New products were in the final stages of commercialization and beginning the limited launch phase Completed the restructuring of the tissue supply chain Mana
Slide 14: 2010 - Reaping the Rewards
2010 - Reaping the Rewards New product revenue continues to increase quarter over quarter Gross margins on new products have been realized Legacy product revenue is stable and growing We are profitable in 2Q 2010 including over $500K in costs for review of strategic alternatives Working capital and
Slide 15: Distribution Effectiveness
Distribution Effectiveness Re-aligned the US agency sales team Transitioned to 38 agencies with 750+ sales reps from 50 agencies with 200 sales reps Allows for deeper penetration in all aspects of orthopedic market Added product specialists to support agencies training and execution Expanded the "sa
Slide 16: Transition to "Hybrid" Sales Model
Transition to "Hybrid" Sales Model Augment the sales model with direct representation Enhance the effectiveness of the agency sales team Better control training, communication and coordination Drive deeper penetration into each account Engage channel partners to handle specialty market areas Assess
Slide 17: Execution on our strategic plan has demonstrated results
Execution on our strategic plan has demonstrated results. We believe the two prong approach we are following to execute on business objectives while reviewing strategic alternatives is the best opportunity for maximizing shareholder value.
Slide 18: Our Stock has Performed Well
Our Stock has Performed Well Relative to our two closest peers, we have outperformed our peers in most periods and our stock price has been improving. And we have not had to raise capital to fund operations.
Slide 19: The Dissident Group
The Dissident Stockholder group is comprised of Heartland Advisors, Inc. Spencer Capital Opportunity Fund, LP Spencer Capital Management, LLC Spencer Capital Partners, LLC Boston Avenue Capital, LLC The Dissident Stockholder nominees are Gary L. Alexander Michelle Rachael Forrest Michael J. McConnel
Slide 20: Dissidents' Strategic Plan
Dissidents' Strategic Plan The Dissidents' nominees lack even basic knowledge of our business, the tissue industry or the markets in which we participate The Dissidents plan to change the business model by licensing one of Osteotech's most important assets - its intellectual property There are large
Slide 21: Dissidents' Strategic Plan-continued
Dissidents' Strategic Plan-continued The Dissidents' nominees lack even basic knowledge of our business, the tissue industry or the markets in which we participate The Dissidents plan to reassess all product lines and shed those that are not core The manufacturing plant for tissue products are self-
Slide 22: Dissidents' Strategic Plan-continued
Dissidents' Strategic Plan-continued The Dissidents' nominees lack even basic knowledge of our business, the tissue industry or the markets in which we participate The Dissidents plan to reduce expenses As noted in our second quarter financial results, we have already significantly reduced expenses,
Slide 23: The Dissident Nominees
The Dissident Nominees In reviewing the background and experience for all of the Dissident Nominees, we could not identify any operational or sales and marketing experience or expertise. We have already pointed out the Dissident Nominees do not have any tissue or biologics industry expertise, which
Slide 24: The Dissidents' strategic plan will consume cash and hurt the bottom line
The Dissidents' strategic plan will accomplish consume cash and negatively impact the bottom line.
Slide 25: Shareholders Rights Plan
Shareholders Rights Plan Adopted as a direct response to the Dissidents acquisition of an 24% ownership position The Board had already engaged Deutsche Bank and was exploring strategic alternatives The rights plan does not include any objectionable provisions
Slide 26: Board Independence
Board Independence We take the independence of our Board very seriously The Dissidents have challenged Mr. Fallon's additional compensation which is directly related to his efforts on the strategic alternatives assessment The largest portion of the compensation is related to the accounting costs ass
Slide 27: Vote for Osteotech's Director Nominees
WE STRONGLY ENCOURAGE OUR SHAREHOLDERS TO VOTE FOR OSTEOTECH'S DIRECTOR NOMINEES BASED ON THEIR BUSINESS, INDUSTRY AND FINANCIAL EXPERIENCE AND EXPERTISE Kenneth P. Fallon, III Sam Owusu-Akyaw Stephen S. Galliker Cato T. Laurencin, M.D., Ph.D. Robert J. Palmisano James M. Shannon To vote for Osteote
Slide 28: Osteotech Product Franchises
Osteotech Product Franchises
Slide 29: Traditional Allograft
Slide 30: Graftech
\ 4 oF) -graftech , in oe J Ae Biologic F
Slide 31: The Gold Standard in DBM
The Gold Standard in DBM
Slide 32: posteorecr:
posteorecr: 45Months PostOp Sie panse. On PROCEDURE “Duel
Slide 33: Osteotech
fhosteotecH
Slide 34: Osteotech
frosteotecH
Slide 35: MagniFuse
frosteotecH: Magnituse- (7a 4 3 oy MagaiPuse 5 <t “ah MagniFuse 7 ) & BONE GnaF . ae “ae He> Magnifuse 8 Ai MaaniPuse 3 &
Slide 36: Osteotech
rosteotecH
Slide 37: BioGenesis
frosteoTecH SBIOGINESS
Slide 38: Osteotech Director Nominee Experience
Osteotech Director Nominee Experience
Slide 39: Kenneth P. Fallon, III
Kenneth P. Fallon, III Mr. Fallon has served as a director of Osteotech since June 1995, and as Chairman of the Board since November 2005. Since March 2004, Mr. Fallon has been an Associate with Kairos Partners, an investment firm and a stockholder that owns approximately 5.3% of our outstanding sto
Slide 40: Sam Owusu-Akyaw
Sam Owusu-Akyaw Mr. Owusu-Akyaw joined Osteotech in July 2004 as President and Chief Operating Officer and as a member of the Board. Since January 2006, he has served in his current position of President, Chief Executive Officer and Director. Prior to joining Osteotech, Mr. Owusu-Akyaw served as Gen
Slide 41: Stephen S. Galliker
Stephen S. Galliker Mr. Galliker has served as a director of Osteotech since March 2004. Mr. Galliker served as Executive Vice President, Finance and Administration, and Chief Financial Officer of Dyax Corp., a biopharmaceutical company, from September 1999 to his retirement in July 2008. He was Chi
Slide 42: Cato T. Laurencin, M.D., Ph.D.
Cato T. Laurencin, M.D., Ph.D. Dr. Laurencin has served as a director of Osteotech since September 2008. Dr. Laurencin is currently the Vice President for Health Affairs at the University of Connecticut Health Center and Dean of the University of Connecticut School of Medicine. At the University of
Slide 43: Robert J. Palmisano
Robert J. Palmisano Mr. Palmisano has served as a director of Osteotech since March 2005. Mr. Palmisano is the former President and Chief Executive Officer of ev3, Inc., a medical device company focused on catheter- based technologies for the endovascular treatment of vascular diseases and disorders
Slide 44: James M. Shannon
James M. Shannon Mr. Shannon has served as a director of Osteotech since March 2007. Since June 2002, Mr. Shannon has been the President and Chief Executive Officer of the National Fire Protection Association (the "NFPA"), an international organization which is the world's leading advocate for fire